The BAIAP2L1 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of A-549 cells that have been subjected to CRISPR/Cas9-mediated disruption of the BAIAP2L1 locus. This polyclonal knockout cell population is provided as a pooled collection of edited cells, enabling loss-of-function studies without the clonal selection bias inherent in single-cell-derived lines. The product is intended for researchers investigating the role of BAIAP2L1 in lung adenocarcinoma biology and associated signaling networks. No specific editing outcome or knockout efficiency is guaranteed; the population reflects the cumulative genetic perturbation across multiple alleles.
The host A-549 cell line is a widely used model of human lung adenocarcinoma, originally derived from the tumor tissue of a 58-year-old male. These adherent epithelial cells are tumorigenic and recapitulate features of alveolar type II epithelium. The A-549 genome harbors a KRAS G12S activating mutation while retaining wild-type EGFR and TP53, making it a relevant system for studying RAS-driven cancers and the contribution of EGFR-dependent signaling to tumor progression.
BAIAP2L1 (also known as IRTKS) encodes an adaptor protein containing an I-BAR domain that functions in membrane curvature sensing and actin cytoskeleton reorganization. It acts downstream of activated receptor tyrosine kinases, including EGFR and the insulin receptor, coupling extracellular stimuli to actin polymerization. BAIAP2L1 interacts with and recruits the WAVE2 complex and Arp2/3 nucleators, along with N-WASP and cortactin, to drive filopodia and lamellipodia formation. Upstream regulators such as Src kinase and STAT3 phosphorylate and modulate BAIAP2L1, while downstream it promotes ??-catenin/TCF transcriptional activity. In this manner, BAIAP2L1 integrates inputs from EGFR, insulin, and integrin adhesion pathways to orchestrate cell migration, invasion, and proliferation.
In A-549 lung adenocarcinoma cells, BAIAP2L1 is implicated in metastatic behavior. EGFR-induced activation of BAIAP2L1 is expected to stimulate WAVE2/Arp2/3-mediated actin polymerization, leading to enhanced membrane protrusion and cell motility. Disruption of BAIAP2L1 in this polyclonal knockout population is predicted to impair these processes, thereby attenuating migration and invasion potential. This model allows dissection of the molecular requirements for lung adenocarcinoma metastasis and may reveal vulnerabilities that can be targeted to limit tumor dissemination.
Researchers can employ this polyclonal knockout model in a range of experimental contexts. Western blotting and RT-qPCR confirm BAIAP2L1 protein and transcript reduction, while Transwell and wound healing assays measure migration and invasion deficits. F-actin phalloidin staining and immunofluorescence reveal cytoskeletal alterations. Cell proliferation and co-immunoprecipitation assays probe BAIAP2L1??s interactions with EGFR, insulin receptor, WAVE2, and cortactin. Applications include mechanistic studies of IRTKS, drug target validation, and anti-invasive compound screening. For further information or technical assistance, please contact Ascent Research.
